Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia

Published:2018-03-05 Issue:5 Volume:2 Page:529-533
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Tran Thai Hoa¹²^ORCID,Harris Marian H.³,Nguyen Jonathan V.²,Blonquist Traci M.⁴^ORCID,Stevenson Kristen E.⁴,Stonerock Eileen⁵,Asselin Barbara L.⁶,Athale Uma H.⁷^ORCID,Clavell Luis A.⁸^ORCID,Cole Peter D.⁹,Kelly Kara M.¹⁰^ORCID,Laverdiere Caroline¹^ORCID,Leclerc Jean-Marie¹,Michon Bruno¹¹^ORCID,Schorin Marshall A.¹²^ORCID,Welch Jennifer J. G.¹³^ORCID,Reshmi Shalini C.⁵^ORCID,Neuberg Donna S.⁴^ORCID,Sallan Stephen E.¹⁴,Loh Mignon L.²^ORCID,Silverman Lewis B.¹⁴

Affiliation:

1. Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montréal, QC, Canada;

2. Helen Diller Family Cancer Research Center, Department of Pediatrics, Benioff Children’s Hospital, University of California, San Francisco, San Francisco, CA;

3. Department of Pathology, Boston Children’s Hospital, Boston, MA;

4. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;

5. Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH;

6. Department of Pediatrics, University of Rochester School of Medicine and Wilmot Cancer Institute, Rochester, NY;

7. Division of Hematology/Oncology, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada;

8. San Jorge Children's Hospital, San Juan, Puerto Rico;

9. Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY;

10. Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York, NY;

11. Département de Pédiatrie, Centre Mère-Enfant Soleil, Centre Hospitalier Universitaire de l’Université Laval, Québec City, QC, Canada;

12. Inova Fairfax Hospital for Children, Falls Church, VA;

13. Division of Pediatric Hematology/Oncology, Hasbro Children's Hospital/Brown University, Providence, RI; and

14. Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

Abstract

Key Points Fifteen percent of NCI high-risk, Ph-negative, B-ALL patients harbored a kinase-activating fusion, and often associated with IKZF1 deletion. IKZF1 deletion represents an independent prognostic factor of poor outcomes, regardless of fusion-positivity.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/5/529/880315/advances014704.pdf

Reference11 articles.

1. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group;Hunger;J Clin Oncol,2012

2. Treatment of childhood acute lymphoblastic leukemia: prognostic factors and clinical advances;Vrooman;Curr Hematol Malig Rep,2016

3. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia;Roberts;N Engl J Med,2014

4. Ph-like acute lymphoblastic leukemia;Tran;Hematology Am Soc Hematol Educ Program,2016

5. Philadelphia chromosome-like acute lymphoblastic leukemia;Tasian;Blood,2017

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia;Biomedicines;2024-01-01

2. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis;Seminars in Diagnostic Pathology;2023-11

3. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia;Leukemia;2023-10-13

4. The international consensus classification of eosinophilic disorders and systemic mastocytosis;American Journal of Hematology;2023-06-07

5. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review;Annals of Hematology;2023-04-27